Blueprint Medicines Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
The Phase III PIONEER study in indolent systemic mastocytosis met the primary endpoint, but the magnitude of benefit came up short of analysts’ expectations.
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Health technology assessment institute NICE said that uncertainty in the clinical evidence for Gavreto means that cost-effectiveness estimates are also uncertain for the drug, which is approved for treating RET fusion-positive advanced non-small cell lung cancer and is reimbursed in 10 European countries.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.